ConductScience.org, home

Paper326550

Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia.

Brandt L and 1 other. Eur J Cancer (1965), 1977. Cited by 19 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia. Papers, record 326550. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326550

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia.
PubMed
Journal
Eur J Cancer (1965)
PubMed
Year
1977
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
1.05
iCite
Revised in PubMed
2019-09-07
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brandt LL
2Könyves II

Source PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LeukemiaMajor topic
PrednisoloneMajor topic
Adolescent
Adult
Aged
Blood Cell Count
Clinical Trials as Topic
Drug Evaluation
Drug Therapy, Combination
Female
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Remission, Spontaneous
Vincristine

Source PubMed

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
7,172,410Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7172410PubMed
7,139,848A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7139848PubMed
6,951,618[Acute leukemias in elderly patients (author's transl)].Blut1982https://conductscience.org/library/papers/6951618PubMed
6,640,823Disposition of orally administered 14C-prednimustine in cancer patients.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6640823PubMed
6,254,684Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6254684PubMed
394,873Prednimustine in adult acute myeloid leukaemia.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/394873PubMed
373,907New cancer chemotherapy drugs in Europe.Cancer Chemother Pharmacol1978https://conductscience.org/library/papers/373907PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/326550

GET https://conductscience.org/api/papers/v1/326550/authors